Method for treating galabiose-binding bacteria infections

Compounds of the formula I

• wherein
• (a) R.sub.1 is selected from the group consisting of
• (i) C.sub.1-24 alkyl;
• (ii) C.sub.2-24 alkenyl;
• (iii) C.sub.2-24 alkynyl;
• (iv) tri(C.sub.1-4 alkyl)silylethyl;
• (v) aryl;
• (vi) mono- and di-halogen-C.sub.1-4 alkyl;
• (vii) aryl substituted with a substituent selected from the group consisting of hydroxy, amino, C.sub.1-4 alkyl, C.sub.1-4 alkoxy, nitro, halogen, and phenoxy;
• (viii) R.sub.3 --(CH.sub.2).sub.n --S--CH.sub.2 CH.sub.2 --
• (ix) (R.sub.3 --(CH.sub.2).sub.n --S--CH.sub.2).sub.2 CHCH.sub.2 --
• (x) R.sub.3 --(CH.sub.2).sub.n --SO.sub.2 --CH.sub.2 CH.sub.2 --
• (xi) (R.sub.3 --(CH.sub.2).sub.n --SO.sub.2 --CH.sub.2).sub.2 CHCH.sub.2 --
• wherein R.sub.3 is selected from the group consisting of H, --COOH, --COO--C.sub.1-4 alkyl, hydroxy, amino, and an inorganic, polymeric or macromolecular carrier, and n is an integer from 1 to 24;
• (xii) Z.sup.1 --S--CH.sub.2 --CH.sub.2 --
• (xiii) (Z.sup.1 --S--CH.sub.2).sub.2 CHCH.sub.2 --
• (xiv) Z.sup.1 --SO.sub.2 --CH.sub.2 --CH.sub.2 --
• (xv) (Z.sup.1 --SO.sub.2 --CH.sub.2).sub.2 CHCH.sub.2 --
• wherein each Z.sup.1 is selected from the group consisting of phenyl and phenyl monosubstituted with hydroxy, amino, C.sub.1-4 alkyl, C.sub.1-4 alkoxy, nitro, halogen, or phenoxy;
• (xvi) R.sub.4 CH.sub.2 CH(CH.sub.2 R.sub.5)CH.sub.2 --
• wherein R.sub.4 and R.sub.5 independently are halogen;
• and
• (xvii) Q--(CH.sub.2).sub.n -- wherein Q is an inorganic, polymeric or macromolecular carrier, and n is an integer from 1 to 24;
• (b) R.sub.2 is selected from the group consisting of glycosidically connected monosaccharide;
• glycosidically connected disaccharide;
• C.sub.1-18 alkyl;
• C.sub.2-18 alkenyl;
• C.sub.2-18 alkynyl;
• C.sub.1-18 alkyloxymethyl;
• C.sub.1-18 alkanoyl;
• .alpha.-hydroxy-C.sub.1-18 alkanoyl;
• naphthyl-, heterocyclyl- or phenyl-C.sub.1-18 alkoxy;
• naphthyl-C.sub.1-8 alkoxy, heterocyclyl-C.sub.1-8 alkoxy, or phenyl-C.sub.1-18 alkoxy where the naphthyl, heterocyclyl or phenyl group is substituted with hydroxyl, amino, C.sub.1-4 alkyl, C.sub.1-4 alkoxy, nitro, halogen, or phenoxy;
• tri(C.sub.1-4 -alkyl)silylethyl;
• tri(C.sub.1-4 -alkyl)silyl;
• tri(C.sub.1-4 -alkyl)silylethoxymethyl;
• halogen;
• .omega.-hydroxy-C.sub.1-4 -alkyl;
• tetrahydropyranyl;
• benzyloxymethyl;
• C.sub.3-8 cycloalkyl;
• monoterpenyl;
• benzoyl;
• and benzoyl monosubstituted with hydroxyl, amino, C.sub.1-4 alkyl, C.sub.1-4 alkoxy, nitro, halogen, or phenoxy;
• the acyl residue of a naturally occurring amino acid;
• and
• R.sub.6 --C(O)--N(R.sub.7)--CH(R.sub.8)--CH.sub.2 --
• wherein R.sub.6 is C.sub.1-4 alkyl;
• phenyl;
• and phenyl substituted with a substituent selected from the group consisting of hydroxyl, amino, C.sub.1-4 alkyl, C.sub.1-4 alkoxy, nitro, halogen, and phenoxy;
• R.sub.7 is H or C.sub.1-4 alkyl;
• and
• R.sub.8 is H, C.sub.1-4 alkyl, or hydroxy-C.sub.1-4 alkyl;
• (c) Z is --O--, --S--, --SO.sub.2 --, or --CH.sub.2 --;
• (d) X is --O--, --S--, --SO.sub.2 --, --CH.sub.2 --, or --NR.sub.10 --, wherein R.sub.10 is H or R.sub.2 above, and R.sub.10 in X and R.sub.1 are optionally connected to form a ring;
• and
• (e) Y is --O-- or --NR.sub.11 -- wherein R.sub.11 is H or R.sub.2 above, and R.sub.11 in X and R.sub.2 are optionally connected to form a ring.